Blinatumomab added to chemotherapy in infant KMT2A-rearranged acute lymphoblastic leukaemia
Adding a single course of the bispecific antibody blinatumomab after induction chemotherapy in infants with KMT2A-rearranged leukaemia raised two-year disease-free survival from a historical 49 percent to 82 percent, the first major advance in infant leukaemia in decades.
Overview
Single-arm phase 2 study of 30 infants with newly diagnosed KMT2A-rearranged ALL treated on the Interfant-06 backbone with one 28-day course of blinatumomab after induction, compared with historical Interfant-06 controls.
Two-year disease-free survival was 81.6 percent against 49.4 percent historically, overall survival 93.3 versus 65.8 percent, and blinatumomab was well tolerated with no treatment discontinuations for toxicity; measurable residual disease became negative or low in almost all infants.
- Two-year disease-free survival 81.6 percent vs 49.4 percent in historical controls.
- Two-year overall survival 93.3 percent vs 65.8 percent.
Blinatumomab after induction is now standard for KMT2A-rearranged infant ALL through the Interfant-21 protocol.
- Thirty patients with historical comparison; longer follow-up needed.
Similar pages
not linked directly; found by shared links- Key paperAcute lymphoblastic leukaemia in children (review)
Shares Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year), New England Journal of Medicine.
- TrialInterfant-06
Shares Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year), Blinatumomab.
- IdeaMenin inhibitors for infant KMT2A-rearranged ALL
Shares Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year), Blinatumomab.
- Key paperINO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL
- TermB-ALL risk groups (NCI criteria, ETV6::RUNX1, hyperdiploidy, hypodiploidy, iAMP21, IKZF1, CNS status)
Shares Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year), Blinatumomab.
- Key paperECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission
- Key paperChildren's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL
- CancerRelapsed and refractory acute lymphoblastic leukaemia in children
Shares Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year), Blinatumomab.